A pioneering science-led techbio company, Genomics formed by world-leading statistical and human geneticists at the University of Oxford, has launched Mystra, the world’s first original AI-enabled human genetics platform, to fundamentally transform drug target discovery and clinical development.

The company’s mission is to use large-scale genetic information to create innovative precision healthcare tools and accelerate drug discovery, helping partners predict, prevent, treat, and cure common diseases like cancer and diabetes. Addressing the pharmaceutical industry’s crisis of a 95% drug candidate failure rate and soaring costs, Genomics developed the Mystra platform over a decade, capitalising on the fact that targets with human genetic support are 2.6 times more likely to succeed in clinical trials.

Mystra is founded upon the world’s largest and most diverse human genotype-phenotype database, which meticulously ingests and harmonizes over 20,000 genome-wide associated studies (GWAS) and trillions of data rows, all augmented by proprietary AI and advanced machine learning.

This technology shifts human genetics from a slow, fragmented, specialist-driven process into a high-speed, integrated capability, allowing biopharma partners to turn complex R&D analysis that once took months into results in a matter of minutes, thereby dramatically increasing the probability of selecting successful drug candidates.

The platform provides a secure and scalable solution for users to build genetic conviction in drug candidates, accelerate R&D, and de-risk investment by connecting cross-functional teams with a shared source of truth for genetic evidence. Life sciences companies can access Mystra's unmatched analytical power through flexible engagement models, including a Self-service (SaaS) option, a Partly Managed model for combining proprietary and Genomics data, or a Fully Managed collaboration with the company’s extensive team of statistical genetic scientists.